28th Apr 2010 16:00
|
For immediate release |
28 April 2010 |
ABCAM PLC
("Abcam" or "the Company")
Director and PDMR Dealings
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, has today been notified that Jane Cooke, a PDMR of the Company, sold 5000 ordinary shares of 1 pence each in the Company at 1195p per share on 27 April 2010 and also sold a further 4029 ordinary shares of 1 pence each at 1163.47p per share on 28 April 2010.
The Company has also been notified of the following transactions under the Abcam plc Share Incentive Plan ("the SIP") to the benefit of the Directors and PDMRs:
|
Name |
Partnership Shares purchased on 26 April 2010 at 1216.95 pence per share |
Matching Shares awarded on 26 April 2010 at 1216.95 pence per share |
Dividend Shares purchased on 26 April 2010 at 1215.95 pence per share |
Subsequent Beneficial Interest in the Company |
Subsequent percentage holding of the Company's issued share capital |
|
Mark Bushfield |
10 |
10 |
2 |
85 |
0.0002% |
|
Philippe Cotrel |
11 |
11 |
7 |
361 |
0.001% |
|
Jane Cooke |
- |
- |
8 |
530 |
0.001% |
|
Jonathan Milner |
- |
- |
8 |
5,739,031 |
15.96% |
|
Jim Warwick |
- |
- |
8 |
580,060 |
1.61% |
|
Jeff Iliffe |
- |
- |
8 |
500 |
0.001% |
The risk of forfeiture attached to the Matching Shares will normally be removed on the third anniversary of the award subject to continued employment and the retention of the Partnership Shares in connection with which they were awarded.
No consideration was paid by the above grantees for the award of the Matching Shares and no consideration is due on their release.
For further information please contact:
|
Abcam |
+ 44 (0) 1223 696000 |
|
Jonathan Milner, Chief Executive Officer |
|
|
Jeffrey Iliffe, Chief Financial Officer |
|
|
|
|
|
Numis Securities |
+ 44 (0) 20 7260 1000 |
|
Michael Meade / Nick Westlake - Nominated Adviser |
|
|
James Black - Corporate Broking |
|
|
|
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
|
Mark Court / Stasa Filiplic |
|
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now has a rapidly growing online catalogue and as at 31 December 2009 it contained 57,960 products, most of which are antibodies, from over 250 suppliers. Abcam employs 250 staff in its four operating companies.
Related Shares:
ABC.L